FDA approves extended-release guanfacine (Intuniv®) as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents - NeLM [2.1.9]
Links shared publicly online about this topic.
- 470total visits
FDA approves extended-release guanfacine (Intuniv®) as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents - NeLM [2.1.9]
View full resource at nelm.nhs.uk
Tags: ADHD, ADHD Medication, Children's Health, FDA, Intuniv, Pediatric ADHD
Most Recently Shared on March 1, 2011 at 8:33 pm By:
FDA approves extended-release guanfacine (Intuniv®) as an adjunctive therapy to stimulants for the treatm... http://bit.ly/gF8pqX #adhd
FDA approves guanfacine ER tablets to treat ADHD in children, teens - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on March 2, 2011 at 7:52 pm By:
FDA approves guanfacine ER tablets to treat ADHD in children, teens: FDA approved the use of once-daily gu... http://bit.ly/hRwbtM #adhd
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants For The Treatment Of ADHD
medicalnewstoday.com — “Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV® (gu” View full resource at medicalnewstoday.com
Most Recently Shared on March 1, 2011 at 8:33 pm By:
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants F... http://bit.ly/ePyJtA #adhd
Medical News: FDA Extends ADHD Drug Indication - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved the non-stimulant guanfacine (Intuniv) for the treatment of attention deficit hyperactivity disorder (ADHD) in combination with other therapies, including stimulants” View full resource at medpagetoday.com
Most Recently Shared on March 1, 2011 at 7:04 am By:
Peter H Brown Doctor and Psychologist
FDA Extends ADHD Drug Indication http://bit.ly/gtokep #ADHD
PharmaLive: FDA Approves Intuniv (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
pharmalive.com — “PharmaLive: FDA Approves Intuniv (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents” View full resource at pharmalive.com
Most Recently Shared on February 28, 2011 at 7:27 pm By:
PharmaLive Pharma and Health News
Daily Advantage - FDA OKs Wider Intuniv Use - http://tinyurl.com/4on7zsc
Medical News: FDA Extends ADHD Drug Indication - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved the non-stimulant guanfacine (Intuniv) for the treatment of attention deficit hyperactivity disorder (ADHD) in combination with other therapies, including stimulants” View full resource at medpagetoday.com
Most Recently Shared on February 28, 2011 at 7:19 pm By:
FDA Extends ADHD Drug Indication http://bit.ly/eeMoee
Intuniv gains indication as adjunctive therapy in ADHD - MPR
empr.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at empr.com
Most Recently Shared on February 28, 2011 at 3:44 pm By:
MPR News: Intuniv gains indication as adjunctive therapy in ADHD: Shire announced that the FDA has approved Intu... http://bit.ly/eyR7Gr
Intuniv gains indication as adjunctive therapy in ADHD - ONA
oncologynurseadvisor.com — “Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6--17 years as part of a total treatment program.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 28, 2011 at 3:40 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Intuniv gains indication as adjunctive therapy in ADHD http://goo.gl/fb/srbUs
Shire: FDA Oks INTUNIV ER Tablets For Use As Adjunctive Therapy To Stimulants
rttnews.com — “Shire plc (SHP.L, SHPGY) said that the US FDA approved the use of once-daily INTUNIV Extended-Release Tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder, also known as ADHD, in children and adolescents ages 6 to 17 as part of a total treatment program.” View full resource at rttnews.com
Most Recently Shared on February 28, 2011 at 3:18 pm By:
Peter H Brown Doctor and Psychologist
Shire: FDA Oks INTUNIV ER Tablets For Use As Adjunctive Therapy To Stimulants http://bit.ly/dUc4ur #ADHD
New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.” View full resource at news-medical.net
Most Recently Shared on May 24, 2010 at 9:05 am By:
New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting: Shire plc, the global spe... http://bit.ly/d1slqM
INTUNIV (Guanfacine) Extended Release Tablets For ADHD In Children And Adolescents Approved By FDA
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV™ (” View full resource at medicalnewstoday.com
Most Recently Shared on September 5, 2009 at 12:05 pm By:
MNT Pediatrics News Pediatrics and Health News
INTUNIV (Guanfacine) Extended Release Tablets For ADHD In Children And Adolescents Approved By FDA: Shire plc (L.. http://bit.ly/2IQcHz
Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
drugs.com — “Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 4, 2009 at 12:32 am By:
FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC
Advertisement
